|
Treatments, n (%)
|
Palbociclib + letrozole (n = 839)
|
Letrozole alone (n = 698)
|
|---|
|
First-line treatment only*
|
448 (53.4)
|
233 (33.4)
|
|
Any second-line treatment received†
|
391 (46.6)
|
465 (66.6)
|
|
CDK4/6 inhibitor
|
165 (42.2)
|
292 (62.9)
|
|
Chemotherapy
|
100 (25.6)
|
44 (9.4)
|
|
Endocrine therapy alone
|
64 (16.4)
|
96 (20.7)
|
|
Other anticancer treatments
|
88 (22.5)
|
56 (12.0)
|
- CDK4/6 cyclin-dependent kinase 4/6, sIPTW stabilized inverse probability of treatment weighting
- *Includes patients who continued treatment, died, or were censored in the first-line setting
- †Patients could have received > 1 category of second-line treatment
